Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis

Iwona Stelmach; Aleksandra Korzeniewska; Katarzyna Smejda; Iwona Jarosz; Włodzimierz Stelmach

Vol 72, No 3-4 (2004)

Research paper

Published online: 2008-02-18

Submitted: 2013-02-22

View PDF (polish)

Download PDF file

Get Citation

Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis

Iwona Stelmach, Aleksandra Korzeniewska, Katarzyna Smejda, Iwona Jarosz, Włodzimierz Stelmach

Pneumonol Alergol Pol 2004;72(3-4):85-89.

Vol 72, No 3-4 (2004)

ORIGINAL PAPERS

Published online: 2008-02-18

Submitted: 2013-02-22

Abstract

Inflammatory process contributes to progressive lung tissue damage in cystic fibrosis(CF). Cysteinyl leukotrienes have been found in the sputum of CF patients at concentrations sufficienttocausepotentbiologicaleffect. This study was designed to assess the effect of anti-inflammatory treatment with montelukast sodium in CF patients.
Twelve patients, aged 6-29 were recruited. It was 20 week, placebo-controlled, and randomized, double blind, crossover trial. At first and last week of each treatment course spirometry and whole body plethysmography parameters (FEV1, PEF, FEF25/75%, VC, TGV, Raw and RV) and clinical wheezing and cough scale were measured. In montelukast group significantimprovementinFEV1(mean±SD,54,6 ± 22,6 before and 62 ± 19,0 after treatment, p = 0.0112) and FEF25/75% (28,9 ± 23,0 before and 37,5 ± 25,5 after treatment, p = 0.0053) were observed. Compared with placebo montelukast significantly improved FEV1(p = 0.0032),PEF(p = 0.0298)andFEF25/75%(p = 0.0091).There was no significant difference in VC, TGV, RawandRV. Montelukast compared with placebo significantlydecreasedcough(p < 0.0001)andwheezing(p = 0.0002)score. In summary, therapy with montelukast may provide clinical benefit to patients with CF.